Persistent Asset Partners Ltd Takes $598,000 Position in Replimune Group, Inc. $REPL

Persistent Asset Partners Ltd acquired a new stake in Replimune Group, Inc. (NASDAQ:REPL) in the fourth quarter, HoldingsChannel reports. The firm acquired 61,488 shares of the company’s stock, valued at approximately $598,000.

Other institutional investors have also modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Replimune Group by 17.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,352 shares of the company’s stock valued at $435,000 after purchasing an additional 6,653 shares during the period. Millennium Management LLC grew its holdings in Replimune Group by 2.8% in the first quarter. Millennium Management LLC now owns 1,223,236 shares of the company’s stock valued at $11,927,000 after purchasing an additional 33,574 shares during the period. Goldman Sachs Group Inc. grew its holdings in Replimune Group by 20.9% in the first quarter. Goldman Sachs Group Inc. now owns 690,167 shares of the company’s stock valued at $6,729,000 after purchasing an additional 119,145 shares during the period. Rhumbline Advisers grew its holdings in Replimune Group by 6.9% in the second quarter. Rhumbline Advisers now owns 102,005 shares of the company’s stock valued at $948,000 after purchasing an additional 6,616 shares during the period. Finally, Sei Investments Co. grew its holdings in Replimune Group by 149.5% in the second quarter. Sei Investments Co. now owns 30,478 shares of the company’s stock valued at $283,000 after purchasing an additional 18,263 shares during the period. Institutional investors and hedge funds own 92.53% of the company’s stock.

Replimune Group Price Performance

REPL opened at $8.78 on Wednesday. The company has a quick ratio of 5.60, a current ratio of 5.60 and a debt-to-equity ratio of 0.33. Replimune Group, Inc. has a 52-week low of $1.50 and a 52-week high of $13.24. The company has a 50 day moving average of $5.27 and a two-hundred day moving average of $7.25. The company has a market cap of $724.99 million, a P/E ratio of -2.55 and a beta of 0.88.

Insider Transactions at Replimune Group

In other Replimune Group news, insider Christopher Sarchi sold 12,000 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $9.24, for a total transaction of $110,880.00. Following the completion of the sale, the insider directly owned 180,962 shares in the company, valued at $1,672,088.88. The trade was a 6.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.20% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. BMO Capital Markets downgraded shares of Replimune Group from a “market perform” rating to an “underperform” rating in a report on Monday, April 13th. Wall Street Zen upgraded shares of Replimune Group from a “strong sell” rating to a “sell” rating in a report on Saturday, May 23rd. Leerink Partners restated a “market perform” rating and issued a $2.00 target price (down from $11.00) on shares of Replimune Group in a report on Monday, April 13th. HC Wainwright restated a “sell” rating on shares of Replimune Group in a report on Monday, April 13th. Finally, Weiss Ratings downgraded shares of Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, June 3rd. Seven research analysts have rated the stock with a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Reduce” and a consensus price target of $4.88.

Replimune Group Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.